Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

7th Eurasian Hematology Oncology Summit
C

How I Treat HL in 2020: What Is the Role of PET-Adapted Strategies? Is BV Superior to Immune CPIs in R/R Disease?

By 7th Eurasian Hematology Oncology Summit FEATURING Christian Gisselbrecht
By 7th Eurasian Hematology Oncology Summit FEATURING Christian Gisselbrecht
193 views
September 30, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
Lymphoma
14:50
7th Eurasian Hematology Oncology Summit

How I Treat Follicular Lymphoma in 2020: Rituximab vs. WW Strategy, …

Feat. G. Gaidano
19:51
7th Eurasian Hematology Oncology Summit

How I Treat DLBCL in 2020: Can Radiotherapy Be Omitted in PET Era? I…

Feat. U. Vitolo
23:29
7th Eurasian Hematology Oncology Summit

2020 Update on IO in R/R cHL: Is Long-Term Therapy w/ Nivo Feasible …

Feat. T. Tuglular
15:27
7th Eurasian Hematology Oncology Summit

How I Treat HL in 2020: What Is the Role of PET-Adapted Strategies? …

Feat. C. Gisselbrecht
21:20
7th Eurasian Hematology Oncology Summit

How I Treat Mantle Cell Lymphoma in 2020: Induction Options, ASCT, a…

Feat. C. Schiffer